National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Recombinant Human Parathyroid Hormone (Natpar®)

Natpar is indicated as adjunctive treatment of adult patients with chronic hypoparathyroidism who cannot be adequately controlled with standard therapy alone.

NCPE Assessment Process Complete
Rapid review commissioned 05/03/2018
Rapid review completed 21/05/2018
Rapid Review outcome A full pharmacoeconomic assessment is recommended to assess the clinical effectiveness and cost effectiveness of Natpar compared with the current standard of care.

The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.